文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症中肾上腺髓质素及抗肾上腺髓质素抗体Adrecizumab的血管效应

Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis.
PubMed 文献 · Shock · 2018-01-01
一句话结论综述指出Adrecizumab(HAM8101)在动物脓毒症模型中减轻炎症、血管渗漏并改善血流动力学、肾功能和生存,安全性良好,是脓毒症辅助治疗的候选药物。

脓毒症时血管张力和血管完整性受损,参与休克发生;游离循环肽肾上腺髓质素(ADM)参与内皮屏障功能和血管张力调节。动物研究显示给予ADM可改善脓毒症结局,但较高剂量ADM可能引起低血压,且ADM半衰期很短、易黏附于表面,限制其临床应用。非中和性抗ADM抗体Adrecizumab(HAM8101)可使血浆ADM持久升高,在全身炎症和脓毒症动物模型中减少炎症、减轻血管渗漏,并改善血流动力学、肾功能和生存;结合动物及I期人体研究显示的良好安全性,Adrecizumab是脓毒症辅助治疗的有前景候选药物。本综述概述ADM在脓毒症中的作用及其对内皮屏障功能和血管舒张的影响,并提出Adrecizumab在脓毒症中可能发挥作用的新机制假说。

要点

  • 脓毒症时血管张力和血管完整性受损,参与休克发生;游离循环ADM参与内皮屏障功能和血管张力调节。
  • 动物研究显示给予ADM可改善脓毒症结局,但较高剂量ADM可能引起低血压,限制其临床适用性。
  • ADM半衰期很短且易黏附于表面,进一步阻碍其临床应用。
  • 非中和性抗ADM抗体Adrecizumab(HAM8101)可使血浆ADM持久升高,在全身炎症和脓毒症动物模型中减少炎症、减轻血管渗漏,并改善血流动力学、肾功能和生存。
  • 结合动物及I期人体研究显示的良好安全性,Adrecizumab是脓毒症辅助治疗的有前景候选药物。

研究设计与关键结果

  • 综述汇总:动物研究显示给予ADM可改善脓毒症结局,但较高剂量ADM可能引起低血压,且ADM半衰期很短、易黏附于表面。
  • 非中和性抗ADM抗体Adrecizumab(HAM8101)可使血浆ADM持久升高,在全身炎症和脓毒症动物模型中减少炎症、减轻血管渗漏,并改善血流动力学、肾功能和生存。
  • 动物及I期人体研究显示Adrecizumab安全性良好,是脓毒症辅助治疗的有前景候选药物。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis remains a major scientific and medical challenge, for which, apart from significant refinements in supportive therapy, treatment has barely changed over the last few decades. During sepsis, both vascular tone and vascular integrity are compromised, and contribute to the development of shock. The free circulating peptide adrenomedullin (ADM) is involved in the regulation of the endothelial barrier function and tone of blood vessels. Several animal studies have shown that ADM administration improves outcome of sepsis. However, in higher dosages, ADM administration may cause hypotension, limiting its clinical applicability. Moreover, ADM has a very short half-life and easily adheres to surfaces, further hampering its clinical use. The non-neutralizing anti-ADM antibody Adrecizumab (HAM8101) which causes a long-lasting increase of plasma ADM has shown promising results in animal models of systemic inflammation and sepsis; it reduced inflammation, attenuated vascular leakage, and improved hemodynamics, kidney function, and survival. Combined with an excellent safety profile derived from animal and phase I human studies, Adrecizumab represents a promising candidate drug for the adjunctive treatment of sepsis. In this review, we first provide a brief overview of the currently available data on the role of adrenomedullin in sepsis and describe its effects on endothelial barrier function and vasodilation. Furthermore, we provide a novel hypothesis concerning the mechanisms of action through which Adrecizumab may exert its beneficial effects in sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Geven C, Bergmann A, Kox M, et al. Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis. Shock. 2018. PMID: 29324626. doi:10.1097/SHK.0000000000001103

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。